Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Generic interferon-beta
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
American Society for Cell Biology Annual Meeting
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
The INCAT disability score: A critical analysis of its measurement properties.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
[Nicolau syndrome after administration of glatiramer acetate].
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
White matter astrocytes in health and disease.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Copolymer 1 inhibits manifestations of graft rejection.

Pages